Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Period	Debt/Equity
2022-12-31	0.14
2023-12-31	0.46
2024-12-31	0.94
2025-12-31	1.84

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRME	$3.16	+10.10%	4.21M
3
4
5

Prime Medicine Inc. (PRME) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Prime Medicine Inc. Data in Excel

More PRME Financial Data